2016
ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition
By Mark J. Feldstein, Ph.D.; Krista E. Bianco
Claim construction is the process in which courts interpret the meaning and scope of a patent's claims. Since the claims "define the invention to which the patentee is entitled the right to exclude," construing the claims can be a critical step in determining the outcome of almost all patent litigations. In fact, the first step of any infringement or validity analysis is to determine the meaning of the claims (i.e., what the claims encompass and what they do not). Only after the boundaries of the claims have been determined can a judge or jury decide whether the allegedly infringing product or process falls within the scope of the patentee's claims, whether the claims are adequately described in the specification, or whether the claims are invalid in view of the prior art. From a practical standpoint, once the scope of the patentee's rights has been determined, the question of infringement can often be resolved without trial, often by agreement of the parties or on summary judgment.
This chapter begins by setting forth the general principles of the claim construction analysis. Once the basic rules for interpreting the meaning of the claims have been explained, this chapter addresses the timing and procedural aspects of the claim construction analysis. Mark J. Feldstein, Ph.D. discusses various strategic considerations the parties to an Abbreviated New Drug Application (ANDA) case should address once the claims have been construed.
Originally printed in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition in 2016. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
Federal Circuit IP Blog
Federal Circuit Reinforces Injury-in-Fact Requirement in Appeals from Post-Grant Proceedings
June 10, 2026
European IP Blog
UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir
8 June 2026
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.